Henry Gómez

Also affiliated with Universidad Ricardo Palma, Instituto Nacional de Enfermedades Neoplásicas, EsSALUD, Centro Peruano de Estudios Sociales

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 7 papers. Top paper: “Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial”.

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial

British Journal of Cancer(2020)10.1038/s41416-020-0786-x

N/A

1.4DataRank · unranked

40 citations

Noam Pondé, Dominique Agbor‐Tarh, Alvaro Moreno‐Aspitia, Martine Piccart, Florentine Hilbers +11 more

Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-22-0069

N/A

0.292DataRank · unranked

6 citations

Sandro Casavilca‐Zambrano, Jeannie Navarro-Vásquez, Carlos A. Castañeda, Guillermo Valencia, Zaida Morante +26 more

Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0607

N/A

0DataRank · unranked

91 citations

Julia D. Wulfkhule, Rosa I. Gallagher, Xiaopeng Sun, Margaret L. Axelrod, Quanhu Sheng +10 more

Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djaa148

N/A

0DataRank · unranked

115 citations

Robert J. Gray, Della Makower, Amir Faghih, Daniel F. Hayes, Charles E. Geyer +23 more

NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0519

N/A

0DataRank · unranked

65 citations

Xiaopeng Sun, Paula I. González-Ericsson, Violeta Sánchez, Melinda E. Sanders, Elizabeth C. Wescott +15 more

Breast cancer subtype and clinical characteristics in women from Peru

Frontiers in Oncology(2023)10.3389/fonc.2023.938042

N/A

0DataRank · unranked

7 citations

Sandro Casavilca‐Zambrano, Jeannie Navarro-Vásquez, Lizeth I. Tamayo, Carlos A. Castañeda, Guillermo Valencia +15 more

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]

ESMO Open(2024)10.1016/j.esmoop.2024.103938

N/A

0DataRank · unranked

9 citations

M. Piccart-Gebhart, Shona Fielding, John Townend, D.W. Hillman, M. Colleoni +37 more